Literature DB >> 22018180

Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation.

R H Straub1, F Buttgereit, M Cutolo.   

Abstract

The investigation of the hypothalamicpituitary-adrenal (HPA) axis in chronic inflammation has demonstrated: 1) an anti-inflammatory influence of the HPA axis; 2) low serum levels of adrenal androgen; 3) equivocal results with respect to levels of adrenocorticotropic hormone and cortisol; 4) inadequately low secretion of adrenal hormones in relation to inflammation (the disproportion principle); 5) modulating role of TNF and IL-6 on the HPA axis; 6) disturbed cooperativity of HPA axis and sympathetic nervous system (uncoupling); 7) observable glucocorticoid resistance; 8) the circadian rhythmicity explains morning symptoms; 9) new medications based on malfunction of the HPA axis (e.g. adapted to the circadian rhythm of hormones and cytokines); and 10) the newly described role of the HPA axis in the context of misguided energy regulation in chronic inflammatory diseases. This review discusses items 1-6 and 10, while the other items are presented elsewhere in this Supplement. Evidence is presented that the basis for many alterations is in an adaptive program positively selected for short-lived inflammatory responses (energy appeal reaction), which becomes a disease-inherent pathogenetic factor, if it continues too long, that can drive systemic disease sequelae of chronic inflammatory diseases such as the metabolic syndrome.

Entities:  

Mesh:

Year:  2011        PMID: 22018180

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  25 in total

Review 1.  Puberty and adolescence as a time of vulnerability to stressors that alter neurobehavioral processes.

Authors:  Mary K Holder; Jeffrey D Blaustein
Journal:  Front Neuroendocrinol       Date:  2013-11-01       Impact factor: 8.606

Review 2.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

3.  Diurnal Salivary Cortisol and Regression Status in MECP2 Duplication Syndrome.

Authors:  Sarika U Peters; Breanne J Byiers; Frank J Symons
Journal:  J Child Neurol       Date:  2015-05-21       Impact factor: 1.987

4.  Phenotypic and Molecular Evidence Suggests That Decrements in Morning and Evening Energy Are Distinct but Related Symptoms.

Authors:  Bradley E Aouizerat; Anand Dhruva; Steven M Paul; Bruce A Cooper; Kord M Kober; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2015-05-29       Impact factor: 3.612

5.  [Neuroimmune connections in inflammation and pain. ImmunoPain].

Authors:  H-G Schaible
Journal:  Z Rheumatol       Date:  2012-10       Impact factor: 1.372

6.  [Depression as a systemic feature of rheumatoid arthritis].

Authors:  M Englbrecht; J Wendler; R Alten
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

7.  Mathematical modeling of the circadian dynamics of the neuroendocrine-immune network in experimentally induced arthritis.

Authors:  R Rao; D DuBois; R Almon; W J Jusko; I P Androulakis
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-05-24       Impact factor: 4.310

8.  Race differences in the relation of vitamins A, C, E, and β-carotene to metabolic and inflammatory biomarkers.

Authors:  Edward C Suarez; Nicole L Schramm-Sapyta
Journal:  Nutr Res       Date:  2013-10-14       Impact factor: 3.315

Review 9.  Depression and cardiovascular disease: an update on how course of illness may influence risk.

Authors:  Jess G Fiedorowicz
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

Review 10.  Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience.

Authors:  Caroline Ménard; Madeline L Pfau; Georgia E Hodes; Scott J Russo
Journal:  Neuropsychopharmacology       Date:  2016-06-13       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.